BIOA
BioAge Labs, Inc.
Biotechnology
Market Cap$641M
5Y Perf.-14.3%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
BIOA vs RVMD vs KYMR vs NUVL vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$30.30B
5Y Perf.+214.2%
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.91B
5Y Perf.+78.8%
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.53B
5Y Perf.+0.1%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.-4.5%
BIOA vs RVMD vs KYMR vs NUVL vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIOA | RVMD | KYMR | NUVL | IMVT |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $641M | $30.30B | $6.91B | $7.53B | $5.53B |
| Revenue (TTM) | $9M | $0.00 | $51M | $0.00 | $0.00 |
| Net Income (TTM) | $-81M | $-1.37B | $-315M | $-450M | $-464M |
| Gross Margin | 99.2% | — | 33.2% | — | — |
| Operating Margin | -10.3% | — | -7.0% | — | — |
| Total Debt | $6M | $159M | $82M | $0.00 | $98K |
| Cash & Equiv. | $189M | $384M | $357M | $262M | $714M |
BIOA vs RVMD vs KYMR vs NUVL vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIOA
RVMD
KYMR
NUVL
IMVT
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 100 | 85.7 | -14.3% |
| Revolution Medicine… (RVMD) | 100 | 314.2 | +214.2% |
| Kymera Therapeutics… (KYMR) | 100 | 178.8 | +78.8% |
| Nuvalent, Inc. (NUVL) | 100 | 100.1 | +0.1% |
| Immunovant, Inc. (IMVT) | 100 | 95.5 | -4.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOA vs RVMD vs KYMR vs NUVL vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BIOA and RVMD are tied at the top with 1 category each (5-stock set) — the right choice depends on your priorities. Revolution Medicines, Inc. is the stronger pick specifically for capital preservation and lower volatility. KYMR, NUVL, and IMVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BIOA
BioAge Labs, Inc.
The Growth Play
BIOA has the current edge in this matchup, primarily because of its strength in growth exposure.
- EPS growth 66.2%
- +338.9% vs NUVL's +53.5%
Best for: growth exposure
RVMD
Revolution Medicines, Inc.
The Income Pick
RVMD is the #2 pick in this set and the best alternative if income & stability is your priority.
- beta 1.08
- Beta 1.08 vs BIOA's 1.41
Best for: income & stability
KYMR
Kymera Therapeutics, Inc.
The Niche Pick
KYMR ranks third and is worth considering specifically for efficiency.
- -22.3% ROA vs RVMD's -59.1%, ROIC -24.9% vs -54.3%
Best for: efficiency
NUVL
Nuvalent, Inc.
The Long-Run Compounder
NUVL is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 446.1% 10Y total return vs RVMD's 393.1%
- Lower volatility, beta 1.09, current ratio 15.27x
- Beta 1.09, current ratio 15.27x
- 1.1% revenue growth vs RVMD's -98.6%
Best for: long-term compounding and sleep-well-at-night
IMVT
Immunovant, Inc.
The Quality Compounder
IMVT is the clearest fit if your priority is quality.
- 3.2% margin vs BIOA's -9.0%
Best for: quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 1.1% revenue growth vs RVMD's -98.6% |
| Quality / Margins | IMVT | 3.2% margin vs BIOA's -9.0% |
| Stability / Safety | RVMD | Beta 1.08 vs BIOA's 1.41 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | BIOA | +338.9% vs NUVL's +53.5% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs RVMD's -59.1%, ROIC -24.9% vs -54.3% |
BIOA vs RVMD vs KYMR vs NUVL vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
BIOA vs RVMD vs KYMR vs NUVL vs IMVT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRVMDLAGGINGIMVT
Who Leads Where
KYMR leads in 2 of 6 categories
RVMD leads 2 • BIOA leads 1 • NUVL leads 0 • IMVT leads 0
Explore the data ↓IMVTImmunovant, Inc.
0leads
NUVLNuvalent, Inc.
0leads
BIOABioAge Labs, Inc.
1leads
KYMRKymera Therapeutics, …
2leads
RVMDRevolution Medicines,…
2leads
6 Total Categories
CATEGORYLEADERvs KYMRvs BIOAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR3/5
Valuation MetricsMultiples, price ratios, and targets
BIOA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYMR4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD3/6
Risk & VolatilityBeta, volatility, and downside exposure
RVMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
KYMR and IMVT operate at a comparable scale, with $51M and $0 in trailing revenue. Profitability is closely matched — net margins range from -6.1% (KYMR) to -9.0% (BIOA).
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… | KYMRKymera Therapeuti… | NUVLNuvalent, Inc. | IMVTImmunovant, Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $9M | $0 | $51M | $0 | $0 |
| EBITDAEarnings before interest/tax | -$93M | -$1.4B | -$352M | -$346M | -$487M |
| Net IncomeAfter-tax profit | -$81M | -$1.4B | -$315M | -$450M | -$464M |
| Free Cash FlowCash after capex | -$82M | -$1.1B | -$244M | -$313M | -$423M |
| Gross MarginGross profit ÷ Revenue | +99.2% | — | +33.2% | — | — |
| Operating MarginEBIT ÷ Revenue | -10.3% | — | -7.0% | — | — |
| Net MarginNet income ÷ Revenue | -9.0% | — | -6.1% | — | — |
| FCF MarginFCF ÷ Revenue | -9.2% | — | -4.7% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +55.5% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +63.5% | -102.7% | +13.4% | -17.8% | +19.7% |
KYMR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
BIOA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… | KYMRKymera Therapeuti… | NUVLNuvalent, Inc. | IMVTImmunovant, Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $641M | $30.3B | $6.9B | $7.5B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $458M | $30.1B | $6.6B | $7.3B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -7.96x | -23.95x | -22.93x | -17.50x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 71.28x | — | 176.26x | — | — |
| Price / BookPrice ÷ Book value/share | 2.35x | 16.61x | 4.52x | 5.96x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
BIOA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
KYMR leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
KYMR delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-83 for RVMD. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), BIOA scores 5/9 vs NUVL's 1/9, reflecting solid financial health.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… | KYMRKymera Therapeuti… | NUVLNuvalent, Inc. | IMVTImmunovant, Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -83.2% | -25.0% | -42.8% | -47.1% |
| ROA (TTM)Return on assets | -25.5% | -59.1% | -22.3% | -37.8% | -44.1% |
| ROICReturn on invested capital | -2.1% | -54.3% | -24.9% | -32.5% | — |
| ROCEReturn on capital employed | -30.7% | -53.0% | -27.2% | -34.4% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 | 4 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.10x | 0.05x | — | 0.00x |
| Net DebtTotal debt minus cash | -$183M | -$225M | -$275M | -$262M | -$714M |
| Cash & Equiv.Liquid assets | $189M | $384M | $357M | $262M | $714M |
| Total DebtShort + long-term debt | $6M | $159M | $82M | $0 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -118.34x | -81.62x | -2119.53x | -26.85x | — |
KYMR leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $54,613 today (with dividends reinvested), compared to $9,732 for BIOA. Over the past 12 months, BIOA leads with a +338.9% total return vs NUVL's +53.5%. The 3-year compound annual growth rate (CAGR) favors RVMD at 80.0% vs BIOA's -0.9% — a key indicator of consistent wealth creation.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… | KYMRKymera Therapeuti… | NUVLNuvalent, Inc. | IMVTImmunovant, Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +38.9% | +80.3% | +16.3% | +1.5% | +5.1% |
| 1-Year ReturnPast 12 months | +338.9% | +278.4% | +190.7% | +53.5% | +96.1% |
| 3-Year ReturnCumulative with dividends | -2.7% | +483.1% | +205.1% | +171.2% | +40.9% |
| 5-Year ReturnCumulative with dividends | -2.7% | +382.1% | +92.1% | +446.1% | +62.4% |
| 10-Year ReturnCumulative with dividends | -2.7% | +393.1% | +154.4% | +446.1% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -0.9% | +80.0% | +45.0% | +39.5% | +12.1% |
RVMD leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
RVMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than BIOA's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 91.5% from its 52-week high vs BIOA's 74.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… | KYMRKymera Therapeuti… | NUVLNuvalent, Inc. | IMVTImmunovant, Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.08x | 1.15x | 1.09x | 1.37x |
| 52-Week HighHighest price in past year | $24.00 | $155.70 | $103.00 | $113.02 | $30.09 |
| 52-Week LowLowest price in past year | $3.67 | $34.00 | $28.06 | $63.56 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +74.3% | +91.5% | +82.2% | +90.6% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 66.4 | 54.1 | 52.9 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 464K | 2.9M | 602K | 544K | 1.4M |
RVMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BIOA as "Buy", RVMD as "Buy", KYMR as "Buy", NUVL as "Buy", IMVT as "Buy". Consensus price targets imply 152.5% upside for BIOA (target: $45) vs 8.6% for RVMD (target: $155).
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… | KYMRKymera Therapeuti… | NUVLNuvalent, Inc. | IMVTImmunovant, Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $45.00 | $154.80 | $117.06 | $144.40 | $45.50 |
| # AnalystsCovering analysts | 3 | 22 | 26 | 14 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RVMD leads in 2 (Total Returns, Risk & Volatility).
Best OverallRevolution Medicines, Inc. (RVMD)Leads 2 of 6 categories
Loading custom metrics...
BIOA vs RVMD vs KYMR vs NUVL vs IMVT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is BIOA or RVMD or KYMR or NUVL or IMVT a better buy right now?
Analysts rate BioAge Labs, Inc.
(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOA or RVMD or KYMR or NUVL or IMVT?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +446. 1%, compared to -2. 7% for BioAge Labs, Inc. (BIOA). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus BIOA's -2. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOA or RVMD or KYMR or NUVL or IMVT?
By beta (market sensitivity over 5 years), Revolution Medicines, Inc.
(RVMD) is the lower-risk stock at 1. 08β versus BioAge Labs, Inc. 's 1. 41β — meaning BIOA is approximately 30% more volatile than RVMD relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOA or RVMD or KYMR or NUVL or IMVT?
On earnings-per-share growth, the picture is similar: BioAge Labs, Inc.
grew EPS 66. 2% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOA or RVMD or KYMR or NUVL or IMVT?
Revolution Medicines, Inc.
(RVMD) is the more profitable company, earning 0. 0% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOA or RVMD or KYMR or NUVL or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BIOA or RVMD or KYMR or NUVL or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Nuvalent, Inc.
(NUVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), +446. 1% 10Y return). Both have compounded well over 10 years (NUVL: +446. 1%, BIOA: -2. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOA and RVMD and KYMR and NUVL and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.